{"id":18837,"date":"2021-02-18T21:12:03","date_gmt":"2021-02-18T19:12:03","guid":{"rendered":"https:\/\/vilkaviskiovsb.lt\/?p=18837"},"modified":"2021-02-18T21:12:03","modified_gmt":"2021-02-18T19:12:03","slug":"lietuva-isigis-papildomu-vakcinos-doziu-is-kompanijos-novavax","status":"publish","type":"post","link":"https:\/\/vilkaviskiovsb.lt\/en\/2021\/02\/18\/lietuva-isigis-papildomu-vakcinos-doziu-is-kompanijos-novavax\/","title":{"rendered":"Lietuva \u012fsigis papildom\u0173 vakcinos dozi\u0173 i\u0161 kompanijos \u201eNovavax\u201c"},"content":{"rendered":"<p><strong>Vyriausyb\u0117 nutar\u0117 \u012fsigyti daugiau nei 16 t\u016bkst. papildom\u0173 vakcinos dozi\u0173 i\u0161 farmacijos kompanijos \u201eNovavax\u201c. Lietuva i\u0161 viso gaus 633 t\u016bkst. \u0161io gamintojo vakcinos dozi\u0173, o j\u0173 tiekimas tur\u0117t\u0173 prasid\u0117ti jau antr\u0105j\u012f \u0161i\u0173 met\u0173 ketvirt\u012f.<\/strong><\/p>\n<p>Europos Komisijai vykdant derybas su \u201eNovavax\u201c Ministr\u0173 kabinetas vasario 3 d. pritar\u0117 620 t\u016bkst. vakcinos dozi\u0173 pirkimui i\u0161 \u0161io gamintojo, ta\u010diau tarp Europos S\u0105jungos (ES) valstybi\u0173 nari\u0173 proporcingai i\u0161dalijus kiekius Lietuvai atiteko kiek daugiau nei 616 t\u016bkst. vakcinos dozi\u0173.<\/p>\n<p>Kai kurios valstyb\u0117s nar\u0117s pageidavo \u012fsigyti ma\u017eiau vakcin\u0173, negu joms buvo si\u016bloma vadovaujantis proporcingumo principu, tod\u0117l likusioms \u0161alims buvo pasi\u016blyta papildom\u0173 vakcin\u0173. Vyriausyb\u0117 sutiko j\u0173 \u012fsigyti, atsi\u017evelgdama \u012f ankstyv\u0105 tiekimo grafik\u0105, paprastas transportavimo ir laikymo s\u0105lygas bei apsaug\u0105 nuo COVID-19 Piet\u0173 Afrikos mutacijos.<\/p>\n<p>Europos S\u0105jungoje \u0161iuo metu yra u\u017eregistruotos ir naudojamos trij\u0173 gamintoj\u0173 vakcinos: \u201eBioNTech &amp; Pfizer\u201c, \u201eModerna\u201c ir \u201eAstraZeneca\u201c. I\u0161ankstin\u0117s sutartys taip pat yra sudarytos su farmacijos kompanijomis \u201eJanssen Pharmaceutica NV\u201c, \u201eSanofi Pasteur &amp; GSK\u201c ir \u201eCureVac\u201c. Europos Komisija taip pat vykdo derybas su kompanijomis \u201eNovavax\u201c ir \u201eValneva\u201c.<\/p>\n<p>Pagal jau sudarytas i\u0161ankstines sutartis Lietuva u\u017esitikrino daugiau nei 9 mln. vakcinos dozi\u0173. \u0160io kieko tur\u0117t\u0173 u\u017etekti paskiepyti daugiau nei 70 proc. \u0161alies gyventoj\u0173. Pasak specialist\u0173, tokia paskiept\u0173 gyventoj\u0173 dalis u\u017etikrint\u0173 kolektyvin\u012f imunitet\u0105 nuo koronaviruso.<\/p>\n<p><em>SAM Spaudos tarnyba<\/em><\/p>","protected":false},"excerpt":{"rendered":"<p>Vyriausyb\u0117 nutar\u0117 \u012fsigyti daugiau nei 16 t\u016bkst. papildom\u0173 vakcinos dozi\u0173 i\u0161 farmacijos kompanijos \u201eNovavax\u201c. Lietuva i\u0161 viso gaus 633 t\u016bkst. \u0161io gamintojo vakcinos dozi\u0173, o j\u0173 tiekimas tur\u0117t\u0173 prasid\u0117ti jau antr\u0105j\u012f \u0161i\u0173 met\u0173 ketvirt\u012f. Europos Komisijai vykdant derybas su \u201eNovavax\u201c Ministr\u0173 kabinetas vasario 3 d. pritar\u0117 620 t\u016bkst. vakcinos dozi\u0173 pirkimui i\u0161 \u0161io gamintojo, ta\u010diau&hellip;<\/p>","protected":false},"author":5,"featured_media":18838,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[100],"tags":[],"class_list":["post-18837","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-del-covid-19","category-100","description-off"],"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/p7kWFe-4TP","jetpack_featured_media_url":"https:\/\/vilkaviskiovsb.lt\/wp-content\/uploads\/2021\/02\/18752_45d2ebbf4045b7f3d23ce206ea58fd5a.jpg","post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/posts\/18837","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/comments?post=18837"}],"version-history":[{"count":1,"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/posts\/18837\/revisions"}],"predecessor-version":[{"id":18839,"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/posts\/18837\/revisions\/18839"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/media\/18838"}],"wp:attachment":[{"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/media?parent=18837"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/categories?post=18837"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/tags?post=18837"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}